Making a meaningful difference

Turning scientific innovation into meaningful impact

Zymeworks is a royalty-driven organization differentiated by in-house R&D capabilities developing novel medicines for patients with difficult-to-treat diseases. Through our proprietary platforms, deep scientific expertise, and global partnerships, we build and manage a portfolio of healthcare assets designed to deliver long-term impact across multiple therapeutic indications.

Partner with us

Integrating partnerships and collaborations is core to our business strategy and allows us to accelerate our efforts to bring novel therapeutics to the broadest group of patients.

News

July 16, 2026

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

June 29, 2026

Zymeworks to Acquire Theravance Biopharma, Inc.

June 14, 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026